版本:
中国

BRIEF-Glycomimetics reports supportive biomarker data from early-stage trial of GMI-1271

May 18 GlycoMimetics Inc-

* GlycoMimetics announces high overall response rates, low induction mortality, promising initial survival outcomes, and supportive biomarker data from phase 1/2 trial of GMI-1271 in AML Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐